A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Capecitabine (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary)
Indications Advanced breast cancer; Ductal carcinoma; Early breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use

18 Jan 2024 Results of patients reported outcomes, published in the Cancer
06 Jun 2023 Results of post-hoc analysis assessing racial differences in disease outcomes and BCM between Black and White patients, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
07 Sep 2022 Planned End Date changed from 31 May 2024 to 29 Mar 2031.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com